{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:29:24Z","timestamp":1784852964060,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001823","name":"Ministry of Education Youth and Sports of the Czech Republic","doi-asserted-by":"publisher","award":["LX22NPO5101"],"award-info":[{"award-number":["LX22NPO5101"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100028365","name":"Nurse Practitioners of Oregon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100028365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Dental Journal"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.identj.2025.100906","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T06:38:42Z","timestamp":1752907122000},"page":"100906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["National Pharmacovigilance Assessment of Oral Adverse Events Following COVID-19 Vaccination in Germany (2020-2023)"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5918-8966","authenticated-orcid":false,"given":"Abanoub","family":"Riad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.identj.2025.100906_bib0001","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.identj.2025.100906_bib0002","article-title":"COVID-19 vaccine-associated myocarditis: analysis of the suspected cases reported to the EudraVigilance and a systematic review of the published literature","volume":"49","author":"Jaiswal","year":"2023","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"11","key":"10.1016\/j.identj.2025.100906_bib0003","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US \u2013 December 14, 2020-January 18, 2021","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.identj.2025.100906_bib0004","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000543182","article-title":"Characteristics of oral adverse effects following COVID-19 vaccination and similarities with oral symptoms in COVID-19 patients: taste and saliva secretory disorders","volume":"34","author":"Tsuchiya","year":"2024","journal-title":"Med Princ Pract"},{"issue":"3","key":"10.1016\/j.identj.2025.100906_bib0005","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.imj.2022.06.004","article-title":"Oral lesions after COVID-19 vaccination: immune mechanisms and clinical approach","volume":"1","author":"Khazeei Tabari","year":"2022","journal-title":"Infect Med"},{"key":"10.1016\/j.identj.2025.100906_bib0006","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.3389\/fpubh.2022.952781","article-title":"Oral adverse events following COVID-19 vaccination: analysis of VAERS reports","volume":"10","author":"Riad","year":"2022","journal-title":"Front Public Health"},{"issue":"5","key":"10.1016\/j.identj.2025.100906_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28771","article-title":"Oral side effects of COVID-19 vaccines in 32 European countries: analysis of EudraVigilance reports","volume":"95","author":"Riad","year":"2023","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.identj.2025.100906_bib0008","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2253589","article-title":"Oral adverse events following COVID-19 and influenza vaccination in Australia","volume":"19","author":"Riad","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.identj.2025.100906_bib0009","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.identj.2025.100906_bib0010","series-title":"Safety of COVID-19 Vaccines","article-title":"Newsroom","year":"2024"},{"key":"10.1016\/j.identj.2025.100906_bib0011","series-title":"Reports submitted to the Paul-Ehrlich-Institut of suspected side effects after the use of COVID-19 vaccines","article-title":"Coronavirus and COVID-19","year":"2024"},{"key":"10.1016\/j.identj.2025.100906_bib0012","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) \u2013 Module IX Addendum I \u2013 methodological aspects of signal detection from spontaneous reports of suspected adverse reactions. 2017 [Accessed 14 February 2025]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-ix-addendum-i-methodological-aspects-signal-detection-spontaneous-reports-suspected-adverse-reactions_en.pdf"},{"issue":"8","key":"10.1016\/j.identj.2025.100906_bib0013","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/life10080138","article-title":"Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance","volume":"10","author":"Park","year":"2020","journal-title":"Life"},{"key":"10.1016\/j.identj.2025.100906_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front Drug Saf Regul"},{"key":"10.1016\/j.identj.2025.100906_bib0015","series-title":"German Infection Protection Act (IfSG)","year":"2001"},{"key":"10.1016\/j.identj.2025.100906_bib0016","unstructured":"US-DHHS. VAERS data use guide. Vaccine Adverse Event Reporting System (VAERS). [Accessed 28 January 2025]. Available from: https:\/\/www.meddra.org\/."},{"issue":"18","key":"10.1016\/j.identj.2025.100906_bib0017","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e174","article-title":"Prevalence and duration of acute loss of smell or taste in COVID-19 patients","volume":"35","author":"Lee","year":"2020","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.identj.2025.100906_bib0018","unstructured":"VAC4EU. EMA-funded studies. [Accessed 14 February 2025]. Available from: https:\/\/vac4eu.org\/ema-funded-studies\/"},{"key":"10.1016\/j.identj.2025.100906_bib0019","unstructured":"Egbers T, Willame C, Belbachir L, et al. ACCESS-background rate of adverse events-definition \u2013anosmia & ageusia [Accessed 10 March 2025]. Available from: https:\/\/zenodo.org\/records\/5236687"},{"issue":"11","key":"10.1016\/j.identj.2025.100906_bib0020","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.vaccine.2022.11.022","article-title":"Anosmia: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"41","author":"Liu","year":"2023","journal-title":"Vaccine"},{"issue":"1_suppl","key":"10.1016\/j.identj.2025.100906_bib0021","doi-asserted-by":"crossref","first-page":"164S","DOI":"10.1177\/01455613241233098","article-title":"Anosmia or ageusia following COVID-19 vaccination: a systematic review","volume":"103","author":"Bahri","year":"2024","journal-title":"Ear Nose Throat J"},{"issue":"9","key":"10.1016\/j.identj.2025.100906_bib0022","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1007\/s00415-022-11188-7","article-title":"Combined central and peripheral demyelination after COVID-19 vaccination","volume":"269","author":"Coelho","year":"2022","journal-title":"J Neurol"},{"issue":"1_suppl","key":"10.1016\/j.identj.2025.100906_bib0023","doi-asserted-by":"crossref","first-page":"164S","DOI":"10.1177\/01455613241233098","article-title":"Anosmia or ageusia following COVID-19 vaccination: a systematic review","volume":"103","author":"Arabzadeh Bahri","year":"2024","journal-title":"Ear Nose Throat J"},{"key":"10.1016\/j.identj.2025.100906_bib0024","unstructured":"European Medicines Agency (EMA). COVID-19 vaccine safety update COMIRNATY BioNTech Manufacturing GmbH. 2021 [Accessed 10 March 2025]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-comirnaty-6-october-2021_en.pdf"},{"issue":"10","key":"10.1016\/j.identj.2025.100906_bib0025","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3390\/ph14101049","article-title":"Side effects of mRNA-based COVID-19 vaccines among young adults (18\u201330 years old): an independent post-marketing study","volume":"14","author":"Riad","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.identj.2025.100906_bib0026","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40001-023-01238-9","article-title":"Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis","volume":"28","author":"Shafiee","year":"2023","journal-title":"Eur J Med Res"},{"issue":"6","key":"10.1016\/j.identj.2025.100906_bib0027","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1016\/j.oooo.2023.12.770","article-title":"Oral herpes zoster following anti-COVID-19 vaccination: is there a relationship?","volume":"137","author":"Boas","year":"2024","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"11","key":"10.1016\/j.identj.2025.100906_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.42240","article-title":"Assessment of herpes zoster risk among recipients of COVID-19 vaccine","volume":"5","author":"Akpandak","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.identj.2025.100906_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e25738","article-title":"The potential association between herpes zoster and COVID-19 vaccination","volume":"10","author":"Pala","year":"2024","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.identj.2025.100906_bib0030","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpag.2021.10.005","article-title":"Vulvar aphthous ulcer in an adolescent after Pfizer-BioNTech (BNT162b2) COVID-19 vaccination","volume":"35","author":"Wojcicki","year":"2021","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"3","key":"10.1016\/j.identj.2025.100906_bib0031","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jormas.2022.01.013","article-title":"Ulcers on the bilateral palate mucosa following mRNA-based vaccination for coronavirus disease 2019 (COVID-19): a case report","volume":"123","author":"Maeda","year":"2022","journal-title":"J Stomatol Oral Maxillofac Surg"},{"issue":"1","key":"10.1016\/j.identj.2025.100906_bib0032","doi-asserted-by":"crossref","first-page":"62","DOI":"10.14476\/jomp.2022.47.1.62","article-title":"A case of aphthous stomatitis in a healthy adult following COVID-19 vaccination: clinical reasoning","volume":"47","author":"Kim","year":"2022","journal-title":"J Oral Med Pain"},{"issue":"3","key":"10.1016\/j.identj.2025.100906_bib0033","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.70178","article-title":"Case report: PFAPA (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) syndrome with a novel TNFAIP3 mutation","volume":"13","author":"Deng","year":"2024","journal-title":"Immun Inflamm Dis"},{"issue":"15","key":"10.1016\/j.identj.2025.100906_bib0034","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/j.vaccine.2022.11.027","article-title":"Anaphylaxis: revision of the Brighton collaboration case definition","volume":"41","author":"Gold","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.identj.2025.100906_bib0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0962280208092342","article-title":"The methodology of self-controlled case series studies","volume":"18","author":"Whitaker","year":"2009","journal-title":"Stat Methods Med Res"},{"issue":"6","key":"10.1016\/j.identj.2025.100906_bib0036","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/joim.12159","article-title":"Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?","volume":"275","author":"Trifir\u00f2","year":"2014","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.identj.2025.100906_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-70653-3","article-title":"Evaluation of the safety profile of rotavirus vaccines: a pharmacovigilance analysis on American and European data","volume":"10","author":"Bonaldo","year":"2020","journal-title":"Sci Rep."},{"issue":"48","key":"10.1016\/j.identj.2025.100906_bib0038","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1016\/j.vaccine.2023.10.030","article-title":"Adverse events of acute nephrotoxicity reported to EudraVigilance and VAERS after COVID-19 vaccination","volume":"41","author":"Anastassopoulou","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.identj.2025.100906_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.756633","article-title":"Frequency and associations of adverse reactions of COVID-19 vaccines reported to pharmacovigilance systems in the European Union and the United States","volume":"9","author":"Montano","year":"2022","journal-title":"Front Public Health."},{"key":"10.1016\/j.identj.2025.100906_bib0040","unstructured":"European Medicines Agency (EMA). Pharmacovigilance: overview. [Accessed 11 March 2025]. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/pharmacovigilance-overview"},{"key":"10.1016\/j.identj.2025.100906_bib0041","series-title":"COVID-19-impfungen nach Geschlecht","article-title":"Gesundheitszustand","year":"2024"},{"key":"10.1016\/j.identj.2025.100906_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1078736","article-title":"Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: a Dutch cohort study and review of the literature","volume":"14","author":"Duijster","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.identj.2025.100906_bib0043","doi-asserted-by":"crossref","unstructured":"Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. 2017 [Accessed 16 November 2021];33:577\u201399. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28992436\/","DOI":"10.1146\/annurev-cellbio-100616-060718"},{"issue":"3","key":"10.1016\/j.identj.2025.100906_bib0044","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.otohns.2010.05.007","article-title":"A practical guide to understanding Kaplan-Meier curves","volume":"143","author":"Rich","year":"2010","journal-title":"Otolaryngol Head Neck Surg"}],"container-title":["International Dental Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0020653925001959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0020653925001959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T15:12:14Z","timestamp":1762182734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0020653925001959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0020653925001959"],"URL":"https:\/\/doi.org\/10.1016\/j.identj.2025.100906","relation":{},"ISSN":["0020-6539"],"issn-type":[{"value":"0020-6539","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National Pharmacovigilance Assessment of Oral Adverse Events Following COVID-19 Vaccination in Germany (2020-2023)","name":"articletitle","label":"Article Title"},{"value":"International Dental Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.identj.2025.100906","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of FDI World Dental Federation.","name":"copyright","label":"Copyright"}],"article-number":"100906"}}